Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders

NCT04175223 | Completed

• 1 other identifier: 19-AOI-03
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 3

Brief Summary

The prevalence of HIV-associated neurocognitive disorders (Human Immunodeficiency Virus) remains high during the era of effective triple therapy. The main clinical phenotypes of cognitive impairment are currently represented by asymptomatic neurocognitive neurocognitive impairment (ANI) and mild neurocognitive disorders (MND). In contrast, HIV-associated dementia has almost disappeared. Among the hypotheses to explain the persistence of such a high prevalence is the persistent activation of the immune system despite virological success. This chronic immune activation is believed to be responsible for an inflammatory response and therefore for accelerated cell aging. Several organ complications in HIV-positive patients have been associated with high markers of immune activation. Among the causes of chronic immune activation in virologically controlled patients, an imbalance in the intestinal flora is suspected. In fact, shortly after HIV infection, the virus causes significant apoptosis of intestinal lymphocytes, responsible for a loss of integrity of the intestinal barrier and an imbalance of flora, defined as "dysbiosis". Loss of epithelial integrity and intestinal dysbiosis are suspected of causing systemic passage of bacterial fragments, of which lypopolisaccharide is best known, resulting in chronic activation of the immune system. Several studies suggest a link between digestive bacterial translocation and HIV-related neurocognitive disorders. An improvement in intestinal dysbiosis could therefore contribute to reducing immune activation and the severity of cognitive impairment. A recent study showed that probiotics can reduce levels of neopterin, a marker of monocytic activation, in the cerebrospinal fluid of HIV-positive patients without neurological symptoms. Our objective is to evaluate the impact of probiotic supplementation on immune activation and cognitive performance in virologically controlled HIV-positive patients with a diagnosis of ANI or MND. The potential improvement of cognition through probiotic treatment could therefore improve their quality of life at a lower cost than a drug and without the risk of serious side effects.

Conditions

HIV; Neurocognitive Disorders

Outcome Measures

Primary Outcomes (1)

• measurement of the immune activation and Serum inflammation markers

  The immune activation is composed with the following elements (quantity of serum immune activation and inflammation markers : sCD14 (ng/mL), sCD163 (ng/mL), TNF-alpha (ng/ml) , IL-1 (ng/ml) , IL-6 (ng/ml) , IL-8 (ng/ml) , D-Dimeres (ng/ml), hCRP (ng/ml), MCP-1(ng/ml), IP-10 (ng/ml), Neurofilaments light chain (log10 ng/ml) and Lipopolysaccharide (ng/ml)) , at inclusion and after 6 months of probiotic supplementation in the 2 groups wwith laboratory tests. The immune activation is the result of the multiple measurements. there is no units of measure and it's not an aggregation of the measurement.

  6 months

Study Arms (2)

probiotics

EXPERIMENTAL

probiotic administration

Dietary Supplement: Vivomixx

without probiotic

NO INTERVENTION

no change from the usual care

Interventions

Vivomixx DIETARY_SUPPLEMENT

probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months

probiotics

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients who have signed informed consent
• Patients infected with HIV-1
• Patients with undetectable viral load and stable antiretroviral therapy for at least 6 months
• Outpatient patients, over 18 years of age
• Patients with social security coverage

You may not qualify if:

• Patients infected with HIV-2
• Patients who have not been on stable antiretroviral therapy and have been virologically successful for at least 6 months
• Patients who have been treated during the primary infection phase, taking into account the potential risks of impact on intestinal lymphocyte apoptosis and therefore on the microbiota
• Patients who do not have HIV-related neurocognitive disorders such as ANI or MND
• Patients refusing to participate in the study

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (3)

CH Cannes

Cannes, 06400, France

Location

CHU Montpellier

Montpellier, 34000, France

Location

CHU de Nice

Nice, 06000, France

Location

MeSH Terms

Conditions

Neurocognitive Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 6, 2019
• First Posted: November 22, 2019
• Study Start: September 19, 2019
• Primary Completion: December 22, 2021
• Study Completion: May 15, 2024
• Last Updated: May 17, 2024

Record last verified: 2024-05

Locations

FR (3)